<DOC>
	<DOCNO>NCT00003620</DOCNO>
	<brief_summary>Phase II trial study effectiveness flavopiridol treat patient chronic lymphocytic leukemia respond treatment fludarabine . Drugs use chemotherapy use different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Determine complete partial response rate flavopiridol patient fludarabine-refractory chronic lymphocytic leukemia . Assess toxicity profile treatment patient . Examine progression-free survival overall survival follow treatment patient . Determine effect flavopiridol normal T-cell subset immunoglobulin level patient . OUTLINE : This open label , multicenter study . Patients register 9/15/2000 receive flavopiridol IV continuously day 1-3 . Treatment repeat every 14 day total 12 course absence disease progression unacceptable toxicity . Patients register 9/15/2000 receive flavopiridol IV 1 hour daily day 1-3 . Treatment repeat every 3 week total 8 course absence disease progression unacceptable toxicity . Patients follow every 3 month first year every 6 month 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Histologically diagnose intermediate risk ( stage I II ) high risk ( stage III IV ) refractory Bcell chronic lymphocytic leukemia Intermediate risk group must evidence active disease show least one following : Massive progressive splenomegaly and/or lymphadenopathy Weight loss great 10 % last 6 month CALGB grade 24 fatigue Fevers great 100.5 degree Fahrenheit OR night sweat great than2 week without evidence infection Progressive lymphocytosis increase great 50 % 2 month period anticipate doubling time le 6 month Refractory fludarabine treatment OR relapse within 6 month fludarabine Lymphocytosis great 5000/mm3 time disease Bilirubin great 1.5 time upper limit normal ( ULN ) Creatinine great 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception No 1 prior nonradiolabeled antibody treatment ( e.g. , Campath1H rituximab ) At least 1 , 3 , prior chemotherapy regimen At least 1 prior chemotherapy regimen comprise fludarabine No concurrent chemotherapy No concurrent chronic use oral corticosteroid No concurrent hormone therapy except nondisease relate condition No concurrent dexamethasone corticosteroidbased antiemetic No concurrent palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>